IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

darolutamide tablets

darolutamide tablets,
for oral use Initial U.S. Approval: 2019

As specified in the prescribing information, darolutamide tablets is indicated for the treatment of prostate cancer. NUBEQA is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Facts about darolutamide tablets

Approval Date: 2019
Proprietary Name: NUBEQA (darolutamide) tablets
Active Ingredient(s): darolutamide
FDA-approved use: prostate cancer
Dosage Form: Tablets: Tablets: 300 mg
Medicine Approved By: European Medical Agency (EMA), Food and Drug Administration (FDA)
Manufacturer: Bayer
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “darolutamide tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For darolutamide tablets

Approved accessible "darolutamide tablets"

Nubeqa (darolutamide) tablets were first approved in 2019. CDER approved it in 2022 to treat metastatic hormone-sensitive prostate cancer in combination with another drug, docetaxel.

NUBEQA is a prescription medicine used to treat men with prostate cancer that has not spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. It is not known if NUBEQA is safe and effective in females. It is not known if NUBEQA is safe and effective in children. Active ingredient: darolutamide Inactive ingredients: calcium hydrogen phosphate, croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone K 30, hypromellose 15 cP, macrogol 3350, and titanium dioxide.

How can 1 go about obtaining darolutamide tablets?

If darolutamide tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

NUBEQA (darolutamide) tablets, for oral use Initial U.S. Approval: 2019

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398